<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clonal expansion of leukemic cells is thought to be due to proliferation in excess of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>To define and compare proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> between various <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), we measured proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdU) incorporation as surrogate markers for proliferation and caspase 3 activity and annexin V surface binding as surrogate markers for activation of the apoptotic cascade in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL), and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) </plain></SENT>
<SENT sid="2" pm="."><plain>We found high proliferation in bone marrow cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> as measured by PCNA and BrdU incorporation </plain></SENT>
<SENT sid="3" pm="."><plain>The lowest level of proliferation was found in CLL </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was also highest in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> as measured by annexin V and caspase 3 activity </plain></SENT>
<SENT sid="5" pm="."><plain>Unexpectedly, we found no significant difference in proliferation in bone marrow CD34+ cells from various <z:hpo ids='HP_0001909'>leukemias</z:hpo> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was significantly higher in bone marrow CD34+ cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:mp ids='MP_0005481'>CML</z:mp> in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase as compared to CD34+ cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="7" pm="."><plain>Our results illustrate differences in proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> between <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0005558'>chronic leukemias</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>These differences may have diagnostic and therapeutic implications </plain></SENT>
</text></document>